Merck announced on October 7, 2025 that it has completed the acquisition of Verona Pharma plc, making the UK‑based biopharmaceutical company a wholly owned subsidiary of the U.S. drugmaker.
The transaction was previously approved by the High Court of Justice of England and Wales on October 6, 2025, and the completion of the deal finalizes the scheme of arrangement under English law.
The acquisition is expected to integrate Verona’s respiratory portfolio into Merck’s global operations, providing access to Merck’s resources and distribution network while concluding the long‑planned transaction for Verona’s shareholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.